



December 11, 2023

Materials Licensing Branch  
*Attn: Frank P. Tran*  
U.S. Nuclear Regulatory Commission, Region III  
2443 Warrenville Rd., Suite 210  
Lisle, IL 60532

SUBJECT: POINT BIOPHARMA USA INC. NOTICE OF NON-CONSUMMATION OF THE PLANNED  
MERGER WITHIN 30 DAYS

Dear Mr. Tran,

On October 3, 2023, POINT Biopharma USA Inc. ("Point USA") submitted to the Nuclear Regulatory Commission ("NRC") a request for written consent to an indirect transfer of control of NRC Materials License number 13-35593-01. The NRC's Written Consent to Indirect License Transfer dated as of November 13 ("Written Consent"), directed Point USA to notify NRC in the event that the transaction will not be consummated within 30 days of the Written Consent. This letter serves as notice to the NRC that the transaction will not be consummated within 30 days of the written notice because the conditions to closing have not yet been satisfied.

If you have any questions or comments pertaining to this notice, please contact Point USA's counsel for nuclear regulatory matters, M. Stanford Blanton, at Balch & Bingham LLP (205-226-3417, [sblanton@balch.com](mailto:sblanton@balch.com)).

Kind Regards,

A handwritten signature in black ink, appearing to read "Michael Abel", written over a horizontal line.

Electronically signed by:  
Michael Abel  
Reason: I am the Author  
Date: Dec 11, 2023 07:49  
EST

Michael Abel

| RECEIVED DEC 12 2023